Ipsilateral Breast Tumor Reappearance and Contralateral Breast Cancer after Primary Breast Cancer Treatment: A Comprehensive Retrospective Study of 15,168 Patients
- 1 January 2018
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 95 (3), 147-155
- https://doi.org/10.1159/000488764
Abstract
Objective: The aim of this retrospective study was to assess the risk factors for developing ipsilateral breast tumor reappearance (IBTR) and de novo contralateral breast cancer (BC) after primary BC treatment. Methods: Retrospectively, 15,168 consecutive patients with primary monolateral BC were enrolled in this monocentric study (from June 1994 to December 2006). Clinicopathological features, follow-up, and survival at 15 years were considered for statistical analysis. Results: Significant associations of increased risk for IBTR were verified with metastatic axillary lymph nodes (HR 1.37 [1.15-1.62], p = 0.0004), high tumor grade G2 (HR 1.35 [1.051.74], p = 0.02) and G3 (HR 1.35 [1.01-1.79], p = 0.04), luminal B (HR 1.51 [1.25-1.82],p < 0.0001), and HER2-positive (HR1.66 [1.14-2.41], p = 0.008) and triple-negative subtype (HR 1.54 [1.07-2.21], p = 0.02).0Ider age (HR 1.44 [1.08-1.91], p = 0.01) and positive family history (HR 1.85 [1.47-2.32], p < 0.0001) were risk factors for contralateral BC. Significant protective factors for IBTR were hormonotherapy (HR 0.71 [0.59-0.85], p = 0.0003), chemotherapy (HR 0.72 [0.60-0.87], p = 0.001), and radiotherapy (HR 0.73 [0.61-0.87], p = 0.0005). Hormonotherapy was also confirmed as a protective factor for contralateral second BC (HR 0.43 [0.30-0.60], p < 0.0001). Conclusions: We classified factors for IBTR and contralateral BC in high-and low-risk groups. In the high-risk group, breast surgery still remains more important than in the low-risk group, which seems to benefit more from adjuvant treatments. (C) 2018 S. Karger AG, BaselKeywords
This publication has 26 references indexed in Scilit:
- Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnosesBreast Cancer Research and Treatment, 2011
- Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapyEuropean Journal Of Cancer, 2010
- Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancerAnnals Of Oncology, 2010
- Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20Journal of Clinical Oncology, 2010
- Incidence and Prognosis of Synchronous and Metachronous Bilateral Breast CancerJournal of Clinical Oncology, 2007
- Cancer Statistics, Trends, and Multiple Primary Cancer Analyses from the Surveillance, Epidemiology, and End Results (SEER) ProgramThe Oncologist, 2007
- Multiple primary tumours in women following breast cancer, 1973–2000British Journal of Cancer, 2006
- Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Five National Surgical Adjuvant Breast and Bowel Project Node-Positive Adjuvant Breast Cancer TrialsJournal of Clinical Oncology, 2006
- Factors Associated With Ipsilateral Breast Failure and Distant Metastases in Patients With Invasive Breast Carcinoma Treated With Breast-Conserving TherapyAmerican Journal of Clinical Pathology, 2003
- Factors Associated With Ipsilateral Breast Failure and Distant Metastases in Patients With Invasive Breast Carcinoma Treated With Breast-Conserving Therapy: A Clinicopathologic Study of 607 Neoplasms From 583 PatientsAmerican Journal of Clinical Pathology, 2003